|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 22.92 USD | -0.17% |
|
-0.69% | -26.35% |
| 08-31 | Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push | RE |
| 08-07 | Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says | MT |
| Market Cap | 2.6B 2.23B 2.1B 1.92B 3.59B 245B 3.6B 24.84B 9.64B 126B 9.75B 9.54B 405B | P/E 2026 * |
-5.77x | P/E 2027 * | -8.89x |
|---|---|---|---|---|---|
| Enterprise Value | 1.81B 1.56B 1.47B 1.34B 2.5B 171B 2.51B 17.31B 6.72B 87.66B 6.8B 6.65B 282B | EV / Sales 2026 * |
64.8x | EV / Sales 2027 * | 9.05x |
| Free-Float |
99.32% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRDN | Delayed | |
CBOE
| VRDN | Real-time | |
|
Boerse Muenchen
| 1S1 | Real-time | |
|
Deutsche Boerse AG
| 1S1 | Delayed | |
|
Börse Stuttgart
| 1S1 | Delayed | |
|
Tradegate
| 1S1 | Real-time |
Last Transcript : Viridian Therapeutics, Inc.
| 1 day | -0.17% | ||
| 1 week | -0.69% | ||
| Current month | -1.04% | ||
| 1 month | +1.82% | ||
| 3 months | +45.25% | ||
| 6 months | -19.12% | ||
| Current year | -26.35% |
| 1 week | 22.39 |  | 23.74 |
| 1 month | 21.62 | | 24.86 |
| Current year | 13.18 | | 34.29 |
| 1 year | 13.18 | | 34.29 |
| 3 years | 9.9 | | 34.29 |
| 5 years | 9.47 | | 39 |
| 10 years | 4.67 | | 270 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 55 | 2023-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 46 | 2023-09-11 |
Kirk Bertelsen
CTO | Chief Tech/Sci/R&D Officer | - | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 74 | 2018-01-02 |
Tomas Kiselak
CHM | Chairman | 39 | 2021-05-31 |
Jennifer Moses
BRD | Director/Board Member | 51 | 2021-07-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/19/26 | Sell | General Counsel | -34,212 | 0.0358% | ||
| 8/14/26 | Exercice | Chief Technology Officer | 80,000 | 0.0838% | ||
| 7/1/26 | Free | Director | 32,341 | 0.0339% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | -0.69% | +22.44% | +20.95% | 2.6B | |
| -2.54% | -2.84% | -1.77% | +14.33% | 48.93B | |
| -0.40% | +1.03% | +418.57% | +527.30% | 45.01B | |
| -1.42% | +2.30% | +42.67% | +22.37% | 44.07B | |
| -1.22% | -2.31% | +4.82% | +77.49% | 40.73B | |
| +0.53% | -1.36% | +16.87% | +46.82% | 33.52B | |
| -0.21% | +9.14% | - | - | 17.77B | |
| -0.35% | -1.56% | +21.42% | +120.75% | 16.5B | |
| -1.01% | +0.50% | +13.91% | +31.83% | 14.67B | |
| -1.65% | -1.03% | +75.93% | +41.12% | 13.77B | |
| Average | -0.84% | +0.41% | +68.32% | +100.33% | 27.76B | |
| Weighted average by Cap. | -1.02% | +0.10% | +88.75% | +127.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.92M 24.03M 22.61M 20.65M 38.63M 2.64B 38.74M 267M 104M 1.35B 105M 103M 4.36B | 232M 199M 187M 171M 320M 21.86B 321M 2.22B 860M 11.22B 870M 851M 36.14B |
| Net income | -466M -401M -377M -345M -645M -44B -647M -4.46B -1.73B -22.57B -1.75B -1.71B -72.73B | -322M -277M -261M -238M -445M -30.4B -447M -3.08B -1.2B -15.6B -1.21B -1.18B -50.24B |
| Net Debt | -787M -677M -637M -582M -1.09B -74.31B -1.09B -7.53B -2.92B -38.13B -2.96B -2.89B -123B | -501M -431M -406M -371M -693M -47.32B -695M -4.8B -1.86B -24.28B -1.88B -1.84B -78.22B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-04 | US$22.92 | -0.17% | 759,915 |
| 26-09-03 | US$22.96 | +0.79% | 1,193,895 |
| 26-09-02 | US$22.78 | -1.09% | 1,417,445 |
| 26-09-01 | US$23.03 | -0.56% | 998,383 |
| 26-08-31 | US$23.16 | +0.35% | 1,048,761 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRDN Stock
Select your edition
All financial news and data tailored to specific country editions
